Cargando…

Cyclin-Dependent Kinase 5 Regulates cPLA2 Activity and Neuroinflammation in Parkinson’s Disease

Hyperactivation of cyclin-dependent kinase 5 (Cdk5) by p25, contributes to neuroinflammation causing neurodegeneration in Parkinson’s disease (PD) and Alzheimer’s disease. However, the mechanism by which Cdk5 induces neuroinflammation in the PD brain is largely unexplored. Here, we show that Cdk5 ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Paul, Sangita, Fatihi, Saman, Sharma, Srishti, Kutum, Rintu, Fields, Raymond, Pant, Harish C., Thukral, Lipi, BK, Binukumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Neuroscience 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698719/
https://www.ncbi.nlm.nih.gov/pubmed/36351818
http://dx.doi.org/10.1523/ENEURO.0180-22.2022
_version_ 1784838890391076864
author Paul, Sangita
Fatihi, Saman
Sharma, Srishti
Kutum, Rintu
Fields, Raymond
Pant, Harish C.
Thukral, Lipi
BK, Binukumar
author_facet Paul, Sangita
Fatihi, Saman
Sharma, Srishti
Kutum, Rintu
Fields, Raymond
Pant, Harish C.
Thukral, Lipi
BK, Binukumar
author_sort Paul, Sangita
collection PubMed
description Hyperactivation of cyclin-dependent kinase 5 (Cdk5) by p25, contributes to neuroinflammation causing neurodegeneration in Parkinson’s disease (PD) and Alzheimer’s disease. However, the mechanism by which Cdk5 induces neuroinflammation in the PD brain is largely unexplored. Here, we show that Cdk5 phosphorylates cytosolic phospholipase A2 (cPLA2) at Thr-268 and Ser-505 sites lead to its activation and generation of eicosanoid products. Mutational studies using site-directed mutagenesis and molecular simulations show that the architecture of the protein changes on each single-point mutation. Interestingly, double mutations also led to a severe decline in the activity of cPLA2 and to the disruption of its translocation to the plasma membrane. Further, the brain lysates of transgenic PD mouse models show hyperactivation of Cdk5, resulting in enhanced phosphorylation of Thr-268 and Ser-505 of cPLA2 and its heightened activity, confirming the findings observed in the cell culture model of PD. These phosphorylation sites of cPLA2 and Cdk5 could be explored as the future therapeutic targets against neuroinflammation in PD. Further, conjoint transcriptomic analysis of the publicly available human PD datasets strengthens the hypothesis that genes of the arachidonic acid, prostaglandin synthesis, and inflammatory pathways are significantly upregulated in the case of PD patients compared with that of healthy control subjects.
format Online
Article
Text
id pubmed-9698719
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Society for Neuroscience
record_format MEDLINE/PubMed
spelling pubmed-96987192022-11-28 Cyclin-Dependent Kinase 5 Regulates cPLA2 Activity and Neuroinflammation in Parkinson’s Disease Paul, Sangita Fatihi, Saman Sharma, Srishti Kutum, Rintu Fields, Raymond Pant, Harish C. Thukral, Lipi BK, Binukumar eNeuro Research Article: New Research Hyperactivation of cyclin-dependent kinase 5 (Cdk5) by p25, contributes to neuroinflammation causing neurodegeneration in Parkinson’s disease (PD) and Alzheimer’s disease. However, the mechanism by which Cdk5 induces neuroinflammation in the PD brain is largely unexplored. Here, we show that Cdk5 phosphorylates cytosolic phospholipase A2 (cPLA2) at Thr-268 and Ser-505 sites lead to its activation and generation of eicosanoid products. Mutational studies using site-directed mutagenesis and molecular simulations show that the architecture of the protein changes on each single-point mutation. Interestingly, double mutations also led to a severe decline in the activity of cPLA2 and to the disruption of its translocation to the plasma membrane. Further, the brain lysates of transgenic PD mouse models show hyperactivation of Cdk5, resulting in enhanced phosphorylation of Thr-268 and Ser-505 of cPLA2 and its heightened activity, confirming the findings observed in the cell culture model of PD. These phosphorylation sites of cPLA2 and Cdk5 could be explored as the future therapeutic targets against neuroinflammation in PD. Further, conjoint transcriptomic analysis of the publicly available human PD datasets strengthens the hypothesis that genes of the arachidonic acid, prostaglandin synthesis, and inflammatory pathways are significantly upregulated in the case of PD patients compared with that of healthy control subjects. Society for Neuroscience 2022-11-22 /pmc/articles/PMC9698719/ /pubmed/36351818 http://dx.doi.org/10.1523/ENEURO.0180-22.2022 Text en Copyright © 2022 Paul et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
spellingShingle Research Article: New Research
Paul, Sangita
Fatihi, Saman
Sharma, Srishti
Kutum, Rintu
Fields, Raymond
Pant, Harish C.
Thukral, Lipi
BK, Binukumar
Cyclin-Dependent Kinase 5 Regulates cPLA2 Activity and Neuroinflammation in Parkinson’s Disease
title Cyclin-Dependent Kinase 5 Regulates cPLA2 Activity and Neuroinflammation in Parkinson’s Disease
title_full Cyclin-Dependent Kinase 5 Regulates cPLA2 Activity and Neuroinflammation in Parkinson’s Disease
title_fullStr Cyclin-Dependent Kinase 5 Regulates cPLA2 Activity and Neuroinflammation in Parkinson’s Disease
title_full_unstemmed Cyclin-Dependent Kinase 5 Regulates cPLA2 Activity and Neuroinflammation in Parkinson’s Disease
title_short Cyclin-Dependent Kinase 5 Regulates cPLA2 Activity and Neuroinflammation in Parkinson’s Disease
title_sort cyclin-dependent kinase 5 regulates cpla2 activity and neuroinflammation in parkinson’s disease
topic Research Article: New Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698719/
https://www.ncbi.nlm.nih.gov/pubmed/36351818
http://dx.doi.org/10.1523/ENEURO.0180-22.2022
work_keys_str_mv AT paulsangita cyclindependentkinase5regulatescpla2activityandneuroinflammationinparkinsonsdisease
AT fatihisaman cyclindependentkinase5regulatescpla2activityandneuroinflammationinparkinsonsdisease
AT sharmasrishti cyclindependentkinase5regulatescpla2activityandneuroinflammationinparkinsonsdisease
AT kutumrintu cyclindependentkinase5regulatescpla2activityandneuroinflammationinparkinsonsdisease
AT fieldsraymond cyclindependentkinase5regulatescpla2activityandneuroinflammationinparkinsonsdisease
AT pantharishc cyclindependentkinase5regulatescpla2activityandneuroinflammationinparkinsonsdisease
AT thukrallipi cyclindependentkinase5regulatescpla2activityandneuroinflammationinparkinsonsdisease
AT bkbinukumar cyclindependentkinase5regulatescpla2activityandneuroinflammationinparkinsonsdisease